FDA Guidance Suggests Distinct Names for Biosimilars
The FDA has issued new guidance that proposes giving distinct non-proprietary names to biologics and biosimilars.
Proposed Co-pay Hike for Military Families Stirs Debate
When Congress resumes session in September, it must also resume negotiations on a tense topic—raising co-pay limits for veterans and military families relying on Tricare health coverage.
FDA’s Oxycodone Decision Offers New Prescribing Information for Treating Kids
Physicians who prescribe opioid analgesics for kids with severe pain will now have the benefit of FDA guidance on pediatric dosing and safety.
Cancer Patients’ Cost Burden Fuels Continued Debate
Rising costs have brought public debate on patient access to cancer medications to a head.
New Study: Preterm Infants without Prophylaxis Suffer Severe RSV
New data confirms what neonatal health care providers and preemie advocates feared – without access to preventative care against respiratory syncytial virus, pre-term infants are suffering severe cases of the deadly disease unnecessarily.
Patients with Respiratory Conditions Struggle to Access Needed Medications
For many Americans with respiratory conditions, the struggle to breathe is now exacerbated by the struggle to pay out-of-pocket expenses for the medications that alleviate their symptoms.
GAfPA Encourages Standards-based Guidelines for Colombia’s Biosimilars
Colombian regulators’ ill-defined “alternative approach” to approving biosimilar medicines has the country’s patients unsettled.
“Best Shot” White Paper Explores Challenges of Senior Citizen Vaccination
If you thought vaccines were just for babies, think again.
Airline Analogy Enlivens Biosimilar Naming Discussions
How can regulators effectively create distinguishable names for biosimilars?
Lieutenant Governors’ “Be the Cure” Initiative Promotes Clinical Trials Participation
The National Lieutenant Governors Association has a message for citizens who want to see cures for Alzheimer’s, cancer, diabetes and other conditions: Participate in clinical trials.
